Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.
Saved in:
| Title: | Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher. |
|---|---|
| Authors: | Bayes, Adam (AUTHOR) |
| Source: | Australasian Psychiatry. Aug2025, Vol. 33 Issue 4, p609-611. 3p. |
| Subjects: | Psilocybin, Post-traumatic stress disorder, Hallucinogenic drugs, Ecstasy (Drug), Medical research, Mental depression |
| Geographic Terms: | Australia |
| Abstract: | Background: Despite a limited evidence base to inform clinicians, Australia has adopted a national approach in rescheduling psilocybin and MDMA as clinical therapies for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), respectively. Purpose: This paper explores clinical research domains warranting further investigation through outlining the reflections of a clinical-academic psychiatrist involved in psychedelic trial work. Results: Eight domains were found to warrant further research investigation including: efficacy, safety (including combining with psychotropics), psychotherapy models, psychological support, therapeutic touch, set/setting and examination of naturalistic data. Conclusions: The clinical availability of psychedelic-assisted therapy (PAT) gives greater impetus for careful research studies, informing treatment and improving patient outcomes. [ABSTRACT FROM AUTHOR] |
| Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Despite a limited evidence base to inform clinicians, Australia has adopted a national approach in rescheduling psilocybin and MDMA as clinical therapies for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), respectively. Purpose: This paper explores clinical research domains warranting further investigation through outlining the reflections of a clinical-academic psychiatrist involved in psychedelic trial work. Results: Eight domains were found to warrant further research investigation including: efficacy, safety (including combining with psychotropics), psychotherapy models, psychological support, therapeutic touch, set/setting and examination of naturalistic data. Conclusions: The clinical availability of psychedelic-assisted therapy (PAT) gives greater impetus for careful research studies, informing treatment and improving patient outcomes. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 10398562 |
| DOI: | 10.1177/10398562251347890 |
